Mayne Pharma acquires dermatology foam portfolio from GSK

GREENVILLE, N.C. — Mayne Pharma on Thursday announced that it had acquired a portfolio of dermatology foam products from GSK in $50.1 million deal. Among the portfolio’s products are U.S. rights to acne treatment Fabior (tazarotene) foam and plaque psoriasis treatment Sorilux (calcipotriene) foam. The company also gains the Canadian rights to Luxiq and Olux-E, as well as Mexican rights to betamethasone foam. 

 

“Mayne Pharma is very attracted to the underlying fundamentals of the US dermatology market,” Mayne Pharma CEO Scott Richards said. “The acquisition will leverage existing commercial infrastructure across functions including sales and marketing, customer service, compliance, medical affairs and contracts administration. We also expect to leverage the new foam capability in future branded and generic product development programs.”

 

Mayne will market Fabior and Sorilux through its specialty brands division and existing sales team. It expects to re-launch both products in FY17, and GSK will continue to distribute the drugs in the interim under a transition services arrangement. 

 

“This acquisition will strengthen Mayne Pharma’s position in the US dermatology market, diversify future branded earnings and create new opportunities for growth,” Richards said. “Both Fabior and Sorilux are a strategic fit with the existing Doryx franchise and participate in attractive and growing markets. We believe both products are differentiated assets with compelling clinical data that physicians and patients will appreciate.”